IRIDEX CORP (IRIX) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for IRIDEX CORP?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, IRIDEX CORP's filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does IRIDEX CORP actually do?
Answer:
IRIDEX Corporation is an ophthalmic medical technology company specializing in treatments for glaucoma and retinal diseases, leveraging its proprietary MicroPulse(R) and Endpoint ManagementTM technologies. These technologies offer low-energy, tissue-sparing laser therapies with improved safety profiles compared to traditional methods. The company's product portfolio includes laser consoles (Cyclo G6, IQ 532/577, PASCAL, OcuLight TX/SLx) and consumable probes, used by ophthalmologists in various clinical settings. IRIDEX generates recurring revenue from consumable sales and service contracts, alongside system sales. In fiscal year 2025, the company reported $52.7 million in revenue and a net loss of $4.4 million.
Question:
What are IRIDEX CORP's revenue drivers?
Answer:
Revenue is driven by the sale of laser consoles, delivery devices, and consumable probes, as well as recurring revenue from service contracts and repair services.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required